Proliferative Diabetic Retinopathy (PDR) Market Report 2024: Strategies And Recent Developments | Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc

The Business Research Company offers in-depth market insights through Proliferative Diabetic Retinopathy (PDR) Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The proliferative diabetic retinopathy (pdr) market size has grown rapidly in recent years. It will grow from $2.16 billion in 2023 to $2.42 billion in 2024 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to growing diabetes prevalence, changes in lifestyle and intake of unhealthy foods, government initiatives, rising numbers of diabetes-related loss of vision.

The proliferative diabetic retinopathy (pdr) market size is expected to see rapid growth in the next few years. It will grow to $3.62 billion in 2028 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to aging population, public awareness and education about diabetes, research and development funding, rising demand for combination therapies. Major trends in the forecast period include advancements in diagnostic technologies, innovations in treatment options, artificial intelligence (ai) for early diagnosis, gene therapy advancements, advanced retinal imaging.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=12911&type=smp

Market Segmentation:
The main treatment types of proliferative diabetic retinopathy are anti-VEGF (vascular endothelial growth factor) therapy, intraocular steroids, laser surgery and vitrectomy. Intraocular steroids are medications administered directly into the eye to manage inflammation and treat conditions like diabetic macular edema or uveitis, helping reduce swelling and improve visual outcomes. The various mode of administration includes injectables, oral and others that are used by various applications such as hospitals, clinics and others.
Proliferative Diabetic Retinopathy PDR Global Market Report 2023 provides data on the global proliferative diabetic retinopathy pdr market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors' revenues, profiles and market shares. The proliferative diabetic retinopathy pdr market report identifies opportunities and strategies based on market trends and leading competitors' approaches.

Major Driver - Rising Diabetes Prevalence Boosts Growth In The Proliferative Diabetic Retinopathy (PDR) Market
The rising prevalence of diabetes is expected to propel the growth of the proliferative diabetic retinopathy (PDR) market going forward. Diabetes is a chronic medical condition characterized by elevated glucose (sugar) levels in the blood. Diabetes is the leading cause of proliferative diabetic retinopathy disease, which can be treated by various methods that prevent further damage to the retina and preserve vision. For instance, in 2021, according to the International Diabetes Federation (IDF), a Belgium-based organization, 537 million adults aged between 20-79 are suffering from diabetes (1 in 10 people) and this number is expected to reach about 643 million by 2030 and 783 million by 2045. Therefore, the rising prevalence of diabetes drives the proliferative diabetic retinopathy (PDR) market.

Competitive Landscape:
Major players in the proliferative diabetic retinopathy (pdr) market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Merck KGaA, Kubota Vision Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Santen Pharmaceutical Co. Ltd., Lupin Limited, Genentech Inc., Sirnaomics Inc.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/proliferative-diabetic-retinopathy-pdr-global-market-report

Top Trend - Innovative Therapies Revolutionize Proliferative Diabetic Retinopathy Treatment Landscape
Major companies operating in the proliferative diabetic retinopathy market continuously focus on developing novel therapies to enhance treatment effectiveness, reduce treatment burden and improve patient outcomes. For example, in June 2022, Biogen, a US-based biotechnology company and Samsung Bioepis, a South Korea-based biotech company, introduced Byooviz (ranibizumab-nuna), the first ophthalmology biosimilar in the US. These products are used to treat patients with diabetic macular edema, proliferative diabetic retinopathy, neovascular age-related macular degeneration (wet AMD) and choroidal neovascularization.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Proliferative Diabetic Retinopathy (PDR) Market Characteristics
3. Proliferative Diabetic Retinopathy (PDR) Market Trends And Strategies
4. Proliferative Diabetic Retinopathy (PDR) Market - Macro Economic Scenario
5. Proliferative Diabetic Retinopathy (PDR) Market Size And Growth
…..
27. Proliferative Diabetic Retinopathy (PDR) Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.